Oppenheimer Maintains Outperform on Zimmer Biomet Holdings, Lowers Price Target to $135

Benzinga · 10/15 12:58
Oppenheimer analyst Steven Lichtman maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Outperform and lowers the price target from $145 to $135.